Rosetta Genomics Ltd.
microRNA biomarkers for cancer diagnosis and prognosis
- Sector
- Biotech
- Headquarters
- REHOVOT, L3
- Latest Form D
- $1.8M, Feb 2012
- Total capital
- $8.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $8.5M
- 4 Form D · last Feb 2012
- 177 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 15
- 25 pending · first 2015
- Rank in peer group#112 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$1.8M
- Private capital raisedForm D · SEC · 3rd filing$1.5M
- Private capital raisedForm D · SEC · 2nd filing$2.5M
- Private capital raisedForm D · SEC · 1st filing$2.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#112 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ayelet ChajutExecutive OfficerNamed in SEC Form D filings
- Brian A MarkisonDirectorNamed in SEC Form D filings
- David SidranskyDirectorNamed in SEC Form D filings
- Gerald Shoshani DogonDirectorNamed in SEC Form D filings
- Isaac Shoshani BentwichDirectorNamed in SEC Form D filings
- Joshua Shoshani RosensweigDirectorNamed in SEC Form D filings
Show all 18 people
- Kenneth BerlinExecutive Officer, DirectorNamed in SEC Form D filings
- Keren GivliExecutive OfficerNamed in SEC Form D filings
- Moshe Shoshani ManyDirectorNamed in SEC Form D filings
- Oded BiranExecutive OfficerNamed in SEC Form D filings
- Racheli Shoshani VizmanExecutive OfficerNamed in SEC Form D filings
- Ranit AharonovExecutive OfficerNamed in SEC Form D filings
- Tali Shoshani Yaron-EldarDirectorNamed in SEC Form D filings
- Tami Fishman JutkowitzExecutive OfficerNamed in SEC Form D filings
- Tina Fishman EdmonstonExecutive OfficerNamed in SEC Form D filings
- Tomer AssisExecutive OfficerNamed in SEC Form D filings
- Tzipora Shoshani KupitzExecutive OfficerNamed in SEC Form D filings
- Yoav Shoshani CheloucheDirectorNamed in SEC Form D filings
What it has protected
USPTO · 15 granted of 40- PendingCompositions And Methods For Determining The Prognosis Of Bladder Urothelial CancerUSPTOApplication 17740067
- PendingCompositions And Methods For Determining The Prognosis Of Bladder Urothelial CancerUSPTOApplication 16402801
- PendingMirna Expression Signature In The Classification Of Thyroid TumorsUSPTOApplication 16192221
Show all 40 patent records
- Compositions And Methods For Determining The Prognosis Of Bladder Urothelial CancerAug 25, 2022 · Application 17740067Pending
- Compositions And Methods For Determining The Prognosis Of Bladder Urothelial CancerMay 7, 2020 · Application 16402801Pending
- Mirna Expression Signature In The Classification Of Thyroid TumorsOct 3, 2019 · Application 16192221Pending
- Gene Expression Signature for Classification of Tissue of Origin of Tumor SamplesAug 8, 2019 · Application 16226406Pending
- Methods And Compositions For Diagnosis Of Alzheimer's DiseaseJun 6, 2019 · Application 16218863Pending
- Targeting Micrornas For The Treatment Of Liver CancerMay 28, 2019 · US 10,301,627Granted
- Methods And Materials For Classification Of Tissue Of Origin Of Tumor SamplesJan 31, 2019 · Application 15909145Pending
- Micrornas and uses thereofJan 10, 2019 · Application 15732957Pending
- Gene Expression Signature For Classification Of Tissue Of Origin Of Tumor SamplesMay 10, 2018 · Application 15853258Pending
- Nucleic Acids Related To MIR-29B-1-5P And Uses ThereofMar 20, 2018 · US 9,920,379Granted
- Nucleic Acid Compositions Related To MIR-138-1-3P And Uses ThereofFeb 13, 2018 · US 9,890,382Granted
- Targeting Micrornas For The Treatment Of Liver CancerDec 19, 2017 · US 9,845,470Granted
- Mirna Expression Signature In The Classification Of Thyroid TumorsDec 14, 2017 · Application 15625645Pending
- Diagnosis And Prognosis Of Various Types Of CancersDec 5, 2017 · US 9,834,821Granted
- Micrornas And Uses ThereofAug 10, 2017 · Application 15731118Pending
- Mirna Expression Signature In The Classification Of Thyroid TumorsJul 18, 2017 · US 9,708,667Granted
- HSA-MIR-146B-5P-RELATED Nucleic Acids And Uses ThereofMay 16, 2017 · US 9,650,679Granted
- Micrornas And Uses ThereofMay 16, 2017 · US 9,650,680Granted
- Viral And Viral Associated Mirnas And Uses ThereofApr 18, 2017 · US 9,624,556Granted
- Methods And Compositions For Diagnosis Of Alzheimer's DiseaseMar 9, 2017 · Application 15097923Pending
- Compositions And Methods For Treatment Of Ovarian CancerJan 19, 2017 · Application 15284693Pending
- Targeting Micrornas For The Treatment Of Liver CancerNov 29, 2016 · US 9,506,062Granted
- Compositions And Methods For Treatment Of Ovarian CancerNov 8, 2016 · US 9,487,781Granted
- Compositions And Methods For Determining The Prognosis Of Bladder Urothelial CancerJun 30, 2016 · Application 14976978Pending
- Compositions And Methods For Prognosis And Treatment Of Prostate CancerJan 26, 2016 · US 9,243,296Granted
- Nucleic Acids Involved In Viral InfectionJan 7, 2016 · Application 14796112Pending
- Detecting Nucleic AcidsDec 31, 2015 · Application 14736521Pending
- Methods And Materials For Classification Of Tissue Of Origin Of Tumor SamplesDec 24, 2015 · Application 14746487Pending
- Targeting Micrornas For The Treatment Of Liver CancerOct 6, 2015 · US 9,150,857Granted
- MicroRNAs and uses thereofSep 15, 2015 · US 9,133,453Granted
- Gene Expression Signature For Classification Of Tissue Of Origin Of Tumor SamplesAug 4, 2015 · US 9,096,906Granted
- Gene Expression Signature For Classification Of Tissue Of Origin Of Tumor SamplesOct 23, 2014 · Application 14320113Pending
- Nucleic acids involved in viral infectionJun 26, 2014 · Application 13986802Pending
- miRNA Expression Signature in the Classification of Thyroid TumorsApplication 61992531Pending
- MicroRNA-based Assay for Diagnosing Thyroid NodulesApplication 62321498Pending
- Mirna Expression Signature In The Classification Of Thyroid TumorsApplication 62139066Pending
- Viral And Viral Associated Mirnas And Uses ThereofApplication 13887506Pending
- Mirna Expression Signature In The Classification Of Thyroid TumorsApplication PCTUS2015030564Pending
- Methods And Materials For Classification Of Tissue Of Origin Of Tumor SamplesApplication 15654168Pending
- Targeting Micrornas For The Treatment Of Liver CancerApplication PCTUS2008081645Pending
Related companies, and why
- Protagenic Therapeutics, Inc.\newSimilar federal contract value in Biotech · null in contracts
- GREENLAB, INC.Similar federal contract value in Biotech · null in contracts
- Advenchen Laboratories, LLCSimilar federal contract value in Biotech · null in contracts
- MatriSys Bioscience, Inc.Similar federal contract value in Biotech · null in contracts
- ProTgen, Inc.Similar federal contract value in Biotech · null in contracts
- PharmaTher Holdings Ltd.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .